Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The telehealth company offers compound Liraglutide starting at $80 per month, Wegovy for $499 per month, and Zepbound for $349 per month
Akalestou E, Miras AD, Rutter GA, le Roux CW
Reported Issues: Consumers report: That the supplement did not lead to weight loss, a reduction in cravings, or appetite suppression as advertised That the product was marketed using misleading claims about GLP-1 support That they paid for a product that did not provide the promised benefits That the supplements are promoted as alternatives to GLP-1 medications, despite not functioning like prescription GLP-1 drugs That marketing materials imply that these supplements are scientifically and medically proven and reliable, when evidence may be lacking That they would not have purchased the supplements if they had known the claims were not supported by reliable scientific evidence Experiencing adverse side effects such as stomach pain, nausea, bloating, diarrhea, increased hunger or weight gain Why Individuals Should Be Concerned: Potential claims include: Economic loss False advertising Performance vs
The Conversation Gets More Complicated One reason this topic has become so challenging is that stopping GLP-1 medications may also carry consequences
The Food and Drug Administration (FDA) considers glutathione safe for consumption in food products, but the National Institutes of Health (NIH) warns that some individuals may experience glutathione side effects
Conference Reports for NATAP Conference on Retroviruses and Opportunistic Infections Denver, Colorado March 3-6 2024 Back Tweet Semaglutide Trims Muscle Volume but Physical Function Not Lost CROI 2024 (Conference on Retroviruses and Opportunistic Infections), March 3-6, 2024, Denver Mark Mascolini Low-dose semaglutide, the GLP-1 receptor agonist that suppresses appetite and lowers weight, significantly decreased psoas muscle volume through 24 weeks in the SLIM LIVER trial of people with HIV infection and metabolic-associated steatotic liver disease (MASLD) [1]
